Birkeland S A, Larsen P O, Larsen F S
J Invest Dermatol. 1981 May;76(5):367-70. doi: 10.1111/1523-1747.ep12520036.
In 28 adults patients with atopic dermatitis participating in a double-blind controlled clinical trial of systemic treatment with a new chromone compound, immune monitoring were performed with a number of in vitro tests. The parameters were phytohemagglutinin, pokeweed mitogen, concanavalin A, purified protein tuberculin derivative, Escherichia coli, Staphylococcus aureus, streptokinase/streptodornase, and allogene lymphocytes in a one-way mixed lymphocyte culture. No benefit could be proven for the drug in the clinical investigation or any change in the immunological tests during the trial. There was no demonstrable differences in the applied immunoparameters between mild and severe atopic dermatitis. The study group was compared with an age- and sex-matched control group and a general tendency to decreased T-cell function in the PHA, PWM, PPD and MLC tests together with a slightly increased HEAC percentage was found in the patients with atopic dermatitis.
在28名参与一种新色酮化合物全身治疗双盲对照临床试验的成年特应性皮炎患者中，通过多项体外试验进行免疫监测。参数包括植物血凝素、商陆有丝分裂原、刀豆球蛋白A、纯化蛋白结核菌素衍生物、大肠杆菌、金黄色葡萄球菌、链激酶/链道酶，以及单向混合淋巴细胞培养中的同种异体淋巴细胞。在临床研究中未证明该药物有任何益处，且试验期间免疫测试无任何变化。轻度和重度特应性皮炎患者在应用的免疫参数上没有明显差异。将研究组与年龄和性别匹配的对照组进行比较，发现特应性皮炎患者在PHA、PWM、PPD和MLC试验中T细胞功能有总体下降趋势，同时HEAC百分比略有增加。
